Skip to main content

APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations

NCT03220035

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations

Associated Conditions

Cancer, All Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on your tumor. A second goal of the study is to evaluate side effects that might be caused by vemurafenib.

This study is currently enrolling.